References
- Graux C, Cools J, Melotte C, Quentmeier H, Ferrando A, Levine R, et al. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet 2004; 36: 1084–1089
- Raanani P, Trakhtenbrot L, Rechavi G, Rosenthal E, Avigdor A, Brok-Simoni F, et al. Philadelphia-chromosome-positive T-lymphoblastic leukemia: acute leukemia or chronic myelogenous leukemia blastic crisis. Acta Haematol 2005; 113: 181–189
- Tchirkov A, Bons J M, Chassagne J, Schoepfer C, Kanold J, Briancon G, et al. Molecular detection of a late-appearing BCR-ABL gene in a child with T-cell acute lymphoblastic leukemia. Ann Hematol 1998; 77: 55–59
- Prebet T, Mozzoconacci M J, Sainty D, Arnquelet C, Lafage M, Dastugue N, et al. Presence of a minor Philadelphia-positive clone in young adults with de novo T-cell ALL. Leuk Lymphoma 2009; 50: 485–487
- Apperley J F. Mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007; 8: 1018–1029
- Quintas-Cardama A, Gibbons D L, Kantarjian H, Talpaz M, Donato N, Cortes J. Sequencing of subcloned PCR products facilitates earlier detection of BCR-ABL1(T315I) and other mutants compared to direct sequencing of the ABL1 kinase domain. Leukemia 2008; 22: 885–888
- Griswold I J, MacPartlin M, Bumm T, Kaled E S, Kantarjian H. Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol 2006; 26: 6082–6093
- Ault P, Cortes J, Koller C, Kaled E S, Kantarjian H. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res 2002; 26: 881–884
- Schaller J L, Burkland G A. Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. MedGenMed 2001; 3: 9
- Cools J, DeAngelo D J, Gotlib J, Stover E H, Legare R D, Cortes J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201–1214